Global Partners L.P. (GLP)
NYSE NYSE Primary 
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 Dosing in the final four study arms has now begun KELOWNA, BC / ACCESSWIRE / July 17, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1 (the "Study") have been received and have already produced several noteworthy findings. Unlimited food and water has been provided to the animals for the entire duration of the Study.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
GLP-1 medicines for obesity are all the rage these days. Viking Therapeutics' candidate has the edge in the speed of weight loss.
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
All three dosing arms have been completed. KELOWNA, BC / ACCESSWIRE / July 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") has now completed all dosing.
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. NYSE: LLY has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo Nordisk A/S NYSE: NVO, best known for Ozempic and Wegovy.
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. NYSE: LLY has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. Mounjaro is prescribed for Type 2 diabetes but is often used off-label for weight loss.
Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier'
Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new report criticized those offerings, saying that they're being acquired through a “shady supplier.”
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025.
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drugs.
GLP-1 drugs and other constraints in Kroger's pharmacies are crimping profits
Grocery-store chain Kroger Co. on Thursday reported better-than-expected first-quarter results, helped in part by more enthusiasm from wealthier shoppers, but executives warned that difficulties in the company's pharmacies would hit second-quarter profits.
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Most of the market focuses on the technology sector, with names like Nvidia Co. NASDAQ: NVDA receiving the lion's share. Among this hype and excitement, those companies worthy of investor capital have been left behind, particularly those in the ‘defensive' space, such as the healthcare sector.
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has now hired a contract research organization ("CRO") to oversee execution of the Company's 12-week chronic study GLP-1-H24-4, (the "Study") which will evaluate various DehydraTECH-GLP-1 (glucagon-like peptide) formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction, and more. Study preparations with the CRO have commenced pursuant to an initial start-up agreement under which a number of activities will occur such as full clinical protocol design and writing in consultation with medical experts, regulatory authority submissions, and data management planning.
Hims & Hers: The Undervalued Gem Poised For Growth
As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already started shipping out injections to subscribers. HIMS stock is still undervalued despite the recent run-up in price, initiating a Buy rating based on subscriber growth, GLP-1 sales estimates, and increased revenues.
